Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-04-29 01:44 CEST (UTC+2h)
 

Multiple dose study for MR product in EU [Regulatives / Guidelines]

posted by jalgorta - Spain, 2017-03-14 14:18  - Posting: # 17156
Views: 300

(edited by Ohlbe on 2017-03-14 17:37)

» For MR products in EMEA, first perform pivotal BE study under fasting state and evaluate the results. If AUC0-t>0.9*AUCinf, you need not to go ahead for steady state BE study. BE under steady state is required when drug accumulates in body. If AUC0-t> 0.9*AUCinf is achieved after signle dose administration, normally, there would not be accumulation.

Hi Samaya, you mention that "first perform pivotal BE under FASTING state"... My question is if you can confirm and reference that the calculation must be under fasting. Since in the case of modified release two conditions are necessary, should be FAST and/or FED???
Kind regards


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
16,784 Posts in 3,605 Threads, 1,033 registered users;
16 users online (0 registered, 16 guests).

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed